INT185350

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 2005
Last Reported 2011
Negated 0
Speculated 0
Reported most in Body
Documents 24
Total Number 24
Disease Relevance 13.21
Pain Relevance 0.35

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (Egfr) cell morphogenesis (Egfr) Golgi apparatus (Egfr)
endoplasmic reticulum (Egfr) intracellular (Egfr) enzyme binding (Egfr)
Anatomy Link Frequency
A549 6
NK cells 2
islets of Langerhans 2
Egfr (Mus musculus)
Pain Link Frequency Relevance Heat
palliative 17 88.56 High High
agonist 1 83.52 Quite High
cytokine 31 69.44 Quite High
metalloproteinase 4 68.36 Quite High
Kinase C 24 68.08 Quite High
COX2 12 65.24 Quite High
addiction 4 60.88 Quite High
Inflammation 10 5.00 Very Low Very Low Very Low
positron emission tomography 8 5.00 Very Low Very Low Very Low
cINOD 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 973 99.96 Very High Very High Very High
Non-small-cell Lung Cancer 462 99.84 Very High Very High Very High
Pancreatic Cancer 254 99.84 Very High Very High Very High
Disease 143 99.40 Very High Very High Very High
Skin Cancer 16 98.92 Very High Very High Very High
Exanthema 122 97.00 Very High Very High Very High
Apoptosis 50 95.60 Very High Very High Very High
Neuroepithelial Neoplasms 18 95.08 Very High Very High Very High
Targeted Disruption 58 90.80 High High
Breast Cancer 10 87.36 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We demonstrated a significant inhibition of EGFR gene expression in both A549 and SPC-A1 cells.
Negative_regulation (inhibition) of Gene_expression (expression) of EGFR gene in A549
1) Confidence 0.59 Published 2005 Journal Genet Vaccines Ther Section Body Doc Link PMC1187910 Disease Relevance 0.49 Pain Relevance 0
In an effort to develop new strategies to block the over expression of EGFR in NSCLC cells, we examined the potential of a dsRNA-mediated specific RNAi approach for silencing the EGFR in NSCLC cell lines in vitro and in vivo.
Negative_regulation (block) of Gene_expression (expression) of EGFR associated with non-small-cell lung cancer
2) Confidence 0.59 Published 2005 Journal Genet Vaccines Ther Section Body Doc Link PMC1187910 Disease Relevance 0.54 Pain Relevance 0
Nevertheless the fact that we successfully inhibited the expression of EGFR as well as the function of EGFR in NSCLC cells provided convincing evidence that RNAi is a very potent technique.
Negative_regulation (inhibited) of Gene_expression (expression) of EGFR associated with non-small-cell lung cancer
3) Confidence 0.59 Published 2005 Journal Genet Vaccines Ther Section Body Doc Link PMC1187910 Disease Relevance 0.33 Pain Relevance 0
Our data showed transfection of NSCLC cells with dsRNA resulted in sequence specific silencing of EGFR with 71.31% and 71.78 % decreases in EGFR protein production and 37.04% and 54.92% in mRNA transcription in A549 and SPC-A1 cells respectively.
Negative_regulation (decreases) of Gene_expression (production) of EGFR in A549 associated with non-small-cell lung cancer
4) Confidence 0.59 Published 2005 Journal Genet Vaccines Ther Section Abstract Doc Link PMC1187910 Disease Relevance 1.01 Pain Relevance 0
Immune fluorescent labeling and flow cytometry were used to monitor the reduction in the production of EGFR protein.
Negative_regulation (reduction) of Gene_expression (production) of EGFR
5) Confidence 0.59 Published 2005 Journal Genet Vaccines Ther Section Abstract Doc Link PMC1187910 Disease Relevance 1.02 Pain Relevance 0
These results convincingly suggested that even an incomplete suppression of EGFR expression was sufficient to hinder growth factor-mediated signaling.
Negative_regulation (suppression) of Gene_expression (expression) of EGFR
6) Confidence 0.59 Published 2005 Journal Genet Vaccines Ther Section Body Doc Link PMC1187910 Disease Relevance 0.52 Pain Relevance 0.03
In our earlier study of patients who underwent GTR we saw a trend toward a negative effect of EGFR and EGFRvIII expression on survival in patients under 40 years of age.
Negative_regulation (effect) of Gene_expression (expression) of EGFR
7) Confidence 0.54 Published 2005 Journal J Transl Med Section Body Doc Link PMC1298339 Disease Relevance 0.32 Pain Relevance 0
The siRNA acts to efficiently downregulate EGFR expression, inhibiting cell growth and enhancing chemosensitivity to TP therapy, resulting in a significant increase in apoptosis.
Negative_regulation (downregulate) of Gene_expression (expression) of EGFR associated with apoptosis
8) Confidence 0.48 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621396 Disease Relevance 0.37 Pain Relevance 0
In the normal pancreas, EGFR expression is limited to ductal cells and the islets of Langerhans (Ueda et al 2004).
Negative_regulation (limited) of Gene_expression (expression) of EGFR in islets of Langerhans
9) Confidence 0.43 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727779 Disease Relevance 0.71 Pain Relevance 0
Further molecular analyses revealed that the down-regulation of EGFR expression was the result of a marked decrease in the transcriptional activity of EGFR.
Negative_regulation (down) of Gene_expression (expression) of EGFR
10) Confidence 0.43 Published 2005 Journal Genet Vaccines Ther Section Body Doc Link PMC1187910 Disease Relevance 0.13 Pain Relevance 0
The decrease in EGFR protein production caused significant growth inhibition, i.e.: reducing the total cell numbers by 85.0% and 78.3 %, and colony forming numbers by 63.3% and 66.8%.
Negative_regulation (decrease) of Gene_expression (production) of EGFR
11) Confidence 0.43 Published 2005 Journal Genet Vaccines Ther Section Abstract Doc Link PMC1187910 Disease Relevance 0.77 Pain Relevance 0
Further molecular analyses revealed that the down-regulation of EGFR expression was the result of a marked decrease in the transcriptional activity of EGFR.
Negative_regulation (regulation) of Gene_expression (expression) of EGFR
12) Confidence 0.43 Published 2005 Journal Genet Vaccines Ther Section Body Doc Link PMC1187910 Disease Relevance 0.13 Pain Relevance 0
ResultsSignificant down-regulation of EGFR gene expression with siRNA specific for EGFR
Negative_regulation (down) of Gene_expression (expression) of EGFR gene
13) Confidence 0.43 Published 2005 Journal Genet Vaccines Ther Section Body Doc Link PMC1187910 Disease Relevance 0.40 Pain Relevance 0
ResultsSignificant down-regulation of EGFR gene expression with siRNA specific for EGFR
Negative_regulation (regulation) of Gene_expression (expression) of EGFR gene
14) Confidence 0.43 Published 2005 Journal Genet Vaccines Ther Section Body Doc Link PMC1187910 Disease Relevance 0.40 Pain Relevance 0
Future directions for EGFR inhibitor therapy in pancreatic cancer
Negative_regulation (inhibitor) of Gene_expression (therapy) of EGFR associated with pancreatic cancer
15) Confidence 0.43 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727779 Disease Relevance 1.07 Pain Relevance 0
Retrospective studies collectively show that over 80% of NSCLC patients who demonstrated clinical response to either gefitinib or erlotinib harbored a mutation within the EGFR tyrosine kinase domain (Paez et al 2004; Lynch et al 2004; Pao and Miller 2005, Takano et al 2005).
Negative_regulation (harbored) of Gene_expression (mutation) of EGFR associated with non-small-cell lung cancer
16) Confidence 0.43 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727779 Disease Relevance 0.48 Pain Relevance 0
The number of the EGFR assessed by a flow cytometry was also in agreement with the immune assay in which dsRNA-EGFR dramatically reduced EGFR gene expression to levels that were 71.31% and 71.78% less than those seen in control groups (P < 0.001).
Negative_regulation (reduced) of Gene_expression (expression) of EGFR gene
17) Confidence 0.43 Published 2005 Journal Genet Vaccines Ther Section Body Doc Link PMC1187910 Disease Relevance 0.19 Pain Relevance 0
As expected, lapatinib reduced levels of p-EGFR, p-HER-2, and p-ERK1/2 in A549 cells.
Negative_regulation (reduced) of Gene_expression (levels) of p-EGFR in A549
18) Confidence 0.40 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2883966 Disease Relevance 0.43 Pain Relevance 0
Erlotinib appears to inhibit both high and moderate EGFR expressing tumor cell lines suggesting that expression is not the only determinant of responsiveness to erlotinib (Desai et al 2002).
Negative_regulation (inhibit) of Gene_expression (expressing) of EGFR associated with cancer
19) Confidence 0.40 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936363 Disease Relevance 0.37 Pain Relevance 0.06
Patients deemed "unresectable" due to extensive tumor invasion and multifocality of disease may have been more likely to have the over expression of the EGFR or the EGFRvIII.
Negative_regulation (have) of Gene_expression (expression) of EGFR associated with cancer and disease
20) Confidence 0.39 Published 2005 Journal J Transl Med Section Body Doc Link PMC1298339 Disease Relevance 1.01 Pain Relevance 0.09

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox